Bicycle Therapeutics Ltd
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase I/II/III clinical trials for the treatment of high nectin-4 expressing tumors; BT552… Read more
Bicycle Therapeutics Ltd (BCYC) - Net Assets
Latest net assets as of September 2025: $618.48 Million USD
Based on the latest financial reports, Bicycle Therapeutics Ltd (BCYC) has net assets worth $618.48 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($763.95 Million) and total liabilities ($145.47 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $618.48 Million |
| % of Total Assets | 80.96% |
| Annual Growth Rate | 77.57% |
| 5-Year Change | 730.78% |
| 10-Year Change | N/A |
| Growth Volatility | 300.78 |
Bicycle Therapeutics Ltd - Net Assets Trend (2016–2024)
This chart illustrates how Bicycle Therapeutics Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Bicycle Therapeutics Ltd (2016–2024)
The table below shows the annual net assets of Bicycle Therapeutics Ltd from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $793.06 Million | +113.80% |
| 2023-12-31 | $370.93 Million | +36.98% |
| 2022-12-31 | $270.78 Million | -21.80% |
| 2021-12-31 | $346.25 Million | +262.72% |
| 2020-12-31 | $95.46 Million | +2.43% |
| 2019-12-31 | $93.20 Million | +233.47% |
| 2018-12-31 | $-69.83 Million | -47.99% |
| 2017-12-31 | $-47.18 Million | -688.04% |
| 2016-12-31 | $8.02 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Bicycle Therapeutics Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 64895400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $890.00K | 0.11% |
| Other Comprehensive Income | $119.00K | 0.02% |
| Other Components | $1.47 Billion | 185.72% |
| Total Equity | $793.06 Million | 100.00% |
Bicycle Therapeutics Ltd Competitors by Market Cap
The table below lists competitors of Bicycle Therapeutics Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
BLUELAKE MINERAL AB
F:5KG0
|
$9.56 Million |
|
Vertiqal Studios Corp.
PINK:VERTF
|
$9.56 Million |
|
MC Mining Ltd
AU:MCM
|
$9.56 Million |
|
Gaming Corps AB
ST:GCOR
|
$9.56 Million |
|
Asmallworld AG
SW:ASWN
|
$9.55 Million |
|
IRLAB Therapeutics AB (publ)
ST:IRLAB-A
|
$9.55 Million |
|
Almondz Global Securities Limited
NSE:ALMONDZ
|
$9.55 Million |
|
PT Puri Sentul Permai Tbk
JK:KDTN
|
$9.55 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bicycle Therapeutics Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 370,932,000 to 793,060,000, a change of 422,128,000 (113.8%).
- Net loss of 169,031,000 reduced equity.
- New share issuances of 544,127,000 increased equity.
- Other comprehensive income increased equity by 1,423,000.
- Other factors increased equity by 45,609,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-169.03 Million | -21.31% |
| Share Issuances | $544.13 Million | +68.61% |
| Other Comprehensive Income | $1.42 Million | +0.18% |
| Other Changes | $45.61 Million | +5.75% |
| Total Change | $- | 113.80% |
Book Value vs Market Value Analysis
This analysis compares Bicycle Therapeutics Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.37x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 11.18x to 0.37x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $0.45 | $5.07 | x |
| 2017-12-31 | $-3.55 | $5.07 | x |
| 2018-12-31 | $-5.25 | $5.07 | x |
| 2019-12-31 | $8.44 | $5.07 | x |
| 2020-12-31 | $4.99 | $5.07 | x |
| 2021-12-31 | $13.82 | $5.07 | x |
| 2022-12-31 | $9.13 | $5.07 | x |
| 2023-12-31 | $10.42 | $5.07 | x |
| 2024-12-31 | $13.62 | $5.07 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bicycle Therapeutics Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -21.31%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -479.18%
- • Asset Turnover: 0.04x
- • Equity Multiplier: 1.21x
- Recent ROE (-21.31%) is above the historical average (-42.84%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -168.37% | 0.00% | 0.00x | 1.47x | $-14.31 Million |
| 2017 | 0.00% | -789.27% | 0.03x | 0.00x | $-11.54 Million |
| 2018 | 0.00% | -306.14% | 0.09x | 0.00x | $-14.86 Million |
| 2019 | -32.84% | -221.78% | 0.13x | 1.18x | $-39.93 Million |
| 2020 | -53.44% | -490.95% | 0.06x | 1.69x | $-60.56 Million |
| 2021 | -19.30% | -571.25% | 0.02x | 1.39x | $-101.44 Million |
| 2022 | -41.63% | -779.35% | 0.04x | 1.52x | $-139.80 Million |
| 2023 | -48.71% | -669.72% | 0.05x | 1.60x | $-217.76 Million |
| 2024 | -21.31% | -479.18% | 0.04x | 1.21x | $-248.34 Million |
Industry Comparison
This section compares Bicycle Therapeutics Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bicycle Therapeutics Ltd (BCYC) | $618.48 Million | -168.37% | 0.24x | $9.55 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |